Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: mutations present in more than 90% of cases. Daraxonrasib is an oral RAS(ON) multiselective, tri-complex inhibitor of the active guanosine triphosphate-bound state of mutant and wild-type RAS. METHODS: G12 and overall populations. Safety was also assessed. RESULTS: G12 population was 7.3 months with daraxonrasib and 3.5 months with chemotherapy, and that in the overall population was 7.2 months and 3.6 months, respectively; the hazard ratios were 0.45 and 0.49, respectively (P<0.001 for both comparisons). Adverse events that occurred after the start of treatment were reported in all the patients in the daraxonrasib group and in 97.7% of those in the chemotherapy group; the incidence of adverse events of grade 3 or higher was 61.8% and 69.6%, respectively. Treatment-related adverse events that led to treatment discontinuation occurred in 1.2% of the patients in the daraxonrasib group and in 11.2% of those in the chemotherapy group. CONCLUSIONS: Among patients with previously treated mPDAC, treatment with daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. (Funded by Revolution Medicines; RASolute 302 ClinicalTrials.gov number, NCT06625320.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this trial, daraxonrasib significantly improved overall survival and progression-free survival compared with chemotherapy.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [59]
In the citing paper
“In the overall population, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy, and median progression-free survival was 7.2 versus 3.6 months, respectively.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [59]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Integrated genomic characterization of pancreatic ductal adenocarcinoma
Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019
Park, W., Chawla, A., & O’Reilly, E. M. (2021) · JAMA · doi:10.1001/jama.2021.13027 · Cited by 1,882
Self-citationPancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Conroy, T., Pfeiffer, P., Vilgrain, V., Lamarca, A., Seufferlein, T., O’Reilly, E. M., Hackert, T., Golan, T., Prager, G., Haustermans, K., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.08.009 · Cited by 610
Self-citationWainberg, Z. A., Melisi, D., Macarulla, T., Pazo Cid, R., Chandana, S. R., De La Fouchardière, C., Dean, A., Kiss, I., Lee, W. J., Goetze, T. O., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01366-1 · Cited by 516
Self-citationMultidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Grossberg, A. J., Chu, L. C., Deig, C. R., Fishman, E. K., Hwang, W. L., Maitra, A., Marks, D. L., Mehta, A., Nabavizadeh, N., Simeone, D. M., et al. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21626 · Cited by 489
Therapeutic developments in pancreatic cancer
Hu, Z. I., & O’Reilly, E. M. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 413
Self-citation
Research works printed but not linked: 1
- Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin 2026;76(1):e70043-e70043.41528114
Cited by
Items 201–226 of 226
KRAS in pancreatic cancer: from molecular biology to transformative therapeutics
Abdelhakeem, A. A. F., Ganatra, N., Gul, K., Saxena, H., Mohammed, N., Ashraf, A., Jones, J. C., Carr, R., Bekaii‐Saab, T., Borad, M. J., et al. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01863-x
Self-citationKocher, F., & Petzer, V. (2026) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-026-01138-8
Thompson, S. K., Yang, Y. C., Quiñones, A. J. L., Chang, S., McKinley, J. L., Tomlinson, A. C. A., Tooley, A. S., Wei, X., Flagella, M., Buckl, A., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c02019
Synergizing Against RAS: The Evolving Landscape of Targeted Combinations in Pancreatic Cancer
Ghosh, A. K., Jazieh, K., Xie, H., Parish, M. A., Babiker, H. M., Bekaii‐Saab, T., Goenka, A. H., Knutson, K. L., Pandey, A., Fernández-Zapico, M. E., et al. (2026) · Cancers · doi:10.3390/cancers18213519
Treatment Strategies and Future Directions for Locally Advanced Pancreatic Cancer
Turner, K. M., Gurewitz, J., Frakes, J. M., Denbo, J. W., Malafa, M. P., Hodul, P. J., Kim, D. W., & Sinnamon, A. J. (2026) · Cancers · doi:10.3390/cancers18213520
Bertalmio, N., Marino, F. A. L., Brundu, S., Rustichelli, S., & Giraudo, E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219788
Ramouz, A., Majlesara, A., Khajeh, E., Goeppert, B. F., Springfeld, C., Mieth, M., & Mehrabi, A. (2026) · Medical Sciences · doi:10.3390/medsci14070748
Self-citationAlem, M., Msakem, M., Abbassi, M. B., Keita, D., Amaadour, L., Oualla, K., Benbrahim, Z., Arifi, S., & Mellas, N. (2026) · Journal of Medical and Radiation Oncology · doi:10.53011/jmro.2026.01.03
Obuekwe, C., Ogunoye, B. T., Adelaja, A. T., Ossai, J., Adegbesan, A. C., & Akingbola, A. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.11.04.764269
Ras signaling in cancer: From molecular mechanisms to next-generation therapeutic inhibitors
Hossain, J., Choudhury, D., Bhattacharyya, S., Vedeshachaitanya, B., & Malakar, P. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189751
Pal, A. S., Ojha, A., Yuen, J. G., Bendale, H., Chen, L., Ojima, I., & Ju, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.11.07.765071
Unmet needs beyond precision in gastrointestinal cancers
Ottaiano, A., Carratù, A. C., Sabbatino, F., Cascella, M., Perri, F., Gualillo, O., Zappavigna, S., Caraglia, M., Berretta, M., & Nasti, G. (2026) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2026.1002412
The RAS revolution in gastrointestinal cancers: Where we are and where we go next
Cordani, M., Korc, M., & Li, M. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218963
Overcoming resistance to KRAS inhibition in KRAS/PIK3CA co-mutated colorectal cancerPreprint
Ferret, L., Montaño, J. L., Nayak, K. B., Turnham, R. E., Rivera, C. G., Xu, R., Kongpracha, P., Swaney, D. L., Krogan, N. J., & Gordan, J. D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.11.10.765758
Chen, R., Fu, M., Lin, H., Jiang, Q., Li, C., Xu, L., Wu, R., Zhang, K., Chen, Y., & Wu, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1930284
Vaccines could be a new frontier in KRAS targeting
Pai, H. V., Phillips, R., & Sivakumar, S. (2026) · Nature Medicine · doi:10.1038/s41591-026-04772-1
MORPHOLOGIC AND MOLECULAR CLASSIFICATION OF RHABDOMYOSARCOMA
Lin, W., Lu, Y. C., Somwar, R., & Febres‐Aldana, C. A. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156745
Syed, Y. Y. (2026) · Drugs · doi:10.1007/s40265-026-02414-x
Outcomes of Pancreatectomy with Superior Mesenteric Artery Resection: A Systematic Review
Groot, V. P., Waizy, S., Scheepens, J. C. M., Kinny‐Köster, B., Habib, J. R., Krell, M., Daamen, L. A., Javed, A. A., Sacks, G. D., Hewitt, D. B., et al. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-20922-8
Ma, C., Zhu, H., Li, Z., Qiu, Y., Liu, X., Zhai, X., 蒋奎荣, Lu, Z., Gao, W., & Yin, L. (2026) · Cancer Screening and Prevention · doi:10.14218/csp.2026.00014
Oligometastatic and Oligoprogressive Pancreatic Adenocarcinoma: New Frontiers for Local Therapy
Chang, E., Koay, E., & Ludmir, E. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000858
Multimodal Biomarkers in Pancreatic Cancer: From Early Detection to Precision Therapy
Elghonaimy, E. A., & Aguilera, T. A. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000862
Wan, S., Georgakopoulos‐Soares, I., & Yee, N. S. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16110580
Multidisciplinary Management of Patients With Nonmetastatic Pancreatic Cancer
Hue, J. J., Bernard, V., & Snyder, R. A. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000857
The Emerging Role for Precision Medicine in Pancreatic Cancer
Kamgar, M., Seo, Y. D., Hall, W. A., Evans, D. B., & McFall, T. B. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000860
Targeting the “Undruggable”: Advances in RAS Inhibition for Pancreatic Cancer
Saj, F., Pant, S., & Haldar, S. D. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000856
Self-citation
Metadata
- Authors
- O’Reilly, E. M., Wainberg, Z. A., Hendifar, A. E., Borad, M. J., Pietrantonio, F., Pant, S., Hammel, P., Cremolini, C., Manji, G. A., Oberstein, P. E., Garrido-Laguna, I., Springfeld, C., Azad, N. S., Ueno, M., Chui, S. Y., Zhang, Y., Patel, H., Lee, Y., Salman, Z., & Wolpin, B. M.
- Affiliations
- Memorial Sloan Kettering Cancer Center, New York
- University of California, Los Angeles (US)
- Cedars-Sinai Medical Center (US)
- Mayo Clinic in Arizona (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- The University of Texas MD Anderson Cancer Center (US)
- Université Paris-Saclay (FR)
- University of Pisa (IT)
- Columbia University Irving Medical Center (US)
- NYU Langone Health (US)
- Huntsman Cancer Institute, University of Utah, Salt Lake City
- University Hospital Heidelberg (DE)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Kanagawa Cancer Center (JP)
- Revolution Medicines (United States) (US)
- Dana-Farber Cancer Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2026-07-23
- Volume
- 395
- Issue
- 4
- Pages
- 325-337
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W7162952636
- Cited by
- 147
- References
- 30
- Citations by year
- 2026: 147
- FWCI
- 431.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Revolution Medicines
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- daraxonrasib, metastatic pancreatic ductal adenocarcinoma, RAS inhibitors, previously treated patients, chemotherapy comparison, overall survival, progression-free survival, adverse events, treatment discontinuation
- MeSH terms
- Gain of Function Mutation, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Piperazines, Quality of Life, Time Factors, ras Proteins, Carcinoma, Pancreatic Ductal, Kaplan-Meier Estimate, Response Evaluation Criteria in Solid Tumors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.